Disulfide-Linked IgG Dimers for Homogeneous Antibody Assembly
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing dimeric antibodies produced through chemical crosslinking or engineered disulfide bonds exhibit heterogeneity and instability, limiting their effectiveness as therapeutic agents.
Innovation Solution
A method involving cysteine mutation in IgG antibodies, followed by mild reduction and oxidation under controlled conditions, to form stable disulfide-linked dimers, reducing the number of cysteines and minimizing unwanted bonding, thereby enhancing dimer stability and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If chemical crosslinking is used to produce dimeric antibodies, then dimeric antibodies can be manufactured, but the product exhibits heterogeneity and varying pharmacological effects
Solution Approach 1:
The patent changes the chemical parameters of the crosslinking process by using site-specific cysteine residues instead of random lysine modification. This parameter change transforms the crosslinking reaction from a heterogeneous process to a homogeneous one, where all dimers are formed at the same location with identical stoichiometry, thereby improving manufacturing precision while maintaining ease of manufacture
Solution Approach 2:
The invention applies local quality by introducing cysteine mutations at specific, predetermined locations in the antibody sequence. This ensures that crosslinking occurs only at these designated sites rather than randomly throughout the molecule, creating uniform dimers with consistent pharmacological properties while simplifying the manufacturing process
2Manufacturing precision
If engineered disulfide bonds are used to reduce heterogeneity, then homogeneity is improved, but the products have never received marketing approval and stability issues remain
Solution Approach 1:
The patent employs self-service by utilizing the antibody's own cysteine residues (either native or introduced at specific sites) to form the crosslinking bonds. The antibody molecules crosslink themselves through disulfide bond formation between cysteine residues on different antibody chains, eliminating the need for external crosslinking agents and improving both stability and regulatory acceptance
Solution Approach 2:
The invention creates a composite structure by forming dimers through disulfide bonds between cysteine residues on separate antibody molecules. This composite approach combines multiple antibody units into a stable, homogeneous dimeric structure that maintains the benefits of the original antibodies while achieving improved homogeneity and stability
3Ease of manufacture
If multiple cysteines are present in the antibody chains, then disulfide bonding can occur, but intramolecular bonding increases causing heterogeneity
Solution Approach 1:
The patent applies the taking out principle by removing or eliminating extraneous cysteine residues that could participate in unwanted intramolecular bonding. By retaining only the specific cysteine residues designated for intermolecular crosslinking, the invention prevents heterogeneous intramolecular bonding while maintaining the ability to form desired disulfide bonds for dimerization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces homogeneous disulfide-linked dimeric antibodies with improved stability and reduced intramolecular interactions, enhancing their therapeutic potential.
Implementation Method 1
a cysteine mutation is introduced into a first IgG antibody... reform as chimeric antibodies... subjected to mild oxidizing conditions to form disulfide-linked dimers
Implementation Method 2
combined with a second IgG antibody under mild reducing conditions to reduce disulfide bonds that crosslink the two different heavy chains
Data Source
AI summary
This disclosure relates to dimeric immunotherapeutics that comprise two IgGs that are crosslinked with a disulfide bond. The two IgGs may be chimeras of two different heavy chains, in which one heavy chain includes a cysteine mutation that forms the disulfide bond, and the other heavy chain lacks the cysteine mutation. The presence of a cysteine mutation in only one of the heavy chains of an IgG avoids two disulfide bonds between the two IgGs, which increases the accessible orientations between the two crosslinked IgGs, and also avoids the formation of trimers and higher-order oligomers.